Pharma Focus Asia

WuXi Biologics Announced Construction of a 69 million Integrated Manufacturing Center in Southwest China

WuXi Biologics commenced construction of a new 69 million integrated manufacturing centre for innovative biologics at Chengdu, Southwest China.


The innovative biologics manufacturing centre is to get constructed in 1.3 million square feet in Chengdu.

This facility is going to be the 12th drug substances manufacturing facility (MFG12) for WuXi Biologics.

The new facility will include drug development and commercial manufacturing facilities with an initial bioreactor capacity of 69 million.

WuXi Biologics will apply its extensive expertise as well as a well-established quality system that conforms to the highest international standards at this new integrated manufacturing centre.

The new construction will enable more global partners, create more jobs for local talents, stimulate high growth of the biologics industry in Chengdu as well as accelerate the biologics ecosystem in Southwest China.


NameWuXi Biologics
LocationChengdu, Southwest China
TypeNew Construction
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference